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Abstract
Background: Alzheimer’s disease (AD) is the most common type of dementia, affecting one in eight adults over
65 years of age. The majority of AD cases are sporadic, with unknown etiology, and only 5% of all patients with AD
present the familial monogenic form of the disease. In the present study, our aim was to establish an in vitro cell
model based on patient-specific human neurons to study the pathomechanism of sporadic AD.
Methods: We compared neurons derived from induced pluripotent stem cell (iPSC) lines of patients with early-onset
familial Alzheimer’s disease (fAD), all caused by mutations in the PSEN1 gene; patients with late-onset sporadic
Alzheimer’s disease (sAD); and three control individuals without dementia. The iPSC lines were differentiated toward
mature cortical neurons, and AD pathological hallmarks were analyzed by RT-qPCR, enzyme-linked immunosorbent
assay, and Western blotting methods.
Results: Neurons from patients with fAD and patients with sAD showed increased phosphorylation of TAU protein
at all investigated phosphorylation sites. Relative to the control neurons, neurons derived from patients with fAD
and patients with sAD exhibited higher levels of extracellular amyloid-β 1–40 (Aβ1–40) and amyloid-β 1–42 (Aβ1–42).
However, significantly increased Aβ1–42/Aβ1–40 ratios, which is one of the pathological markers of fAD, were observed
only in samples of patients with fAD. Additionally, we detected increased levels of active glycogen synthase kinase 3 β,
a physiological kinase of TAU, in neurons derived from AD iPSCs, as well as significant upregulation of amyloid
precursor protein (APP) synthesis and APP carboxy-terminal fragment cleavage. Moreover, elevated sensitivity to
oxidative stress, as induced by amyloid oligomers or peroxide, was detected in both fAD- and sAD-derived neurons.
Conclusions: On the basis of the experiments we performed, we can conclude there is no evident difference except
secreted Aβ1–40 levels in phenotype between fAD and sAD samples. To our knowledge, this is the first study in which
the hyperphosphorylation of TAU protein has been compared in fAD and sAD iPSC-derived neurons. Our findings
demonstrate that iPSC technology is suitable to model both fAD and sAD and may provide a platform for developing
new treatment strategies for these conditions.
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Background
There are nearly 47 million people living with dementia
worldwide, which is predicted to double every 20 years,
increasing to more than 131 million by 2050. Alzheimer’s
disease (AD) is the best characterized among them, and it
accounts for 50–60% of all dementia cases [1]. This com-
mon neurodegenerative disease is clinically characterized
by a progressive and gradual cognitive impairment, syn-
apse loss, and substantial loss of neurons in later stages.
Owing to the disease’s heterogeneity, the etiology of AD is
still not very well understood. Most cases of early-onset
AD are linked to autosomal dominant inherited mutations
in the genes encoding amyloid precursor protein (APP),
presenilin 1 (PSEN1), and presenilin 2 (PSEN2). These
cases are referred to as familial Alzheimer’s disease (fAD)
and are well characterized. In contrast, the etiology of the
remaining 95% cases of late-onset AD, often referred to as
sporadic Alzheimer’s disease (sAD), requires further inves-
tigation owing to the various factors involved in the path-
ology, including genetic and environmental exposures [2].
Moreover, cellular changes in the brain precede the first
clinical symptoms by 10–15 years, and there is a lack of
early diagnostic biomarkers for the prodromal stages of
AD. Currently, there is no cure for AD, and the available
medications can only slow down the progression of
dementia and slightly improve the quality of life of the
patients [3].
Two well-defined pathological hallmarks of AD have
been described: the formation of extracellular amyloid
plaques and the development of intracellular neurofibril-
lary tangles (NFTs) formed by aggregated hyperpho-
sphorylated TAU protein [4]. The amyloid plaques are
composed mainly of Aβ and form aggregates of regularly
ordered amyloid fibers [5, 6]. Aβ peptides are derived
from the sequential cleavage of APP by the proteolytic
enzymes β- and γ-secretase. The cleavage of APP by
β-secretase results in production of a large, secreted, de-
rivative soluble amyloid precursor protein β protein and a
99-amino acid membrane-associated fragment (CT99) [7].
The γ-secretase complex cleaves within the transmem-
brane fragment of CT99 at various positions and gener-
ates peptides with differing lengths of the C-terminus
(Aβ1–37, Aβ1–38, Aβ1–40, Aβ1–42, Aβ1–43; reviewed in [8]).
Among these, Aβ1–40 is the most abundant isoform
(~80–90% of the total Aβ peptide) [9], whereas the
Aβ1–42 variant is the main isoform of the amyloid de-
posits found in AD [10, 11]. Aβ1–42 peptides have higher
self-aggregating properties than the less hydrophobic,
smaller Aβ species, and they have the ability to form
oligomers. These diffusible, nonfibrillar, soluble, low-
molecular-weight oligomers have neurotoxic effects [9]. It
has been shown that soluble Aβ oligomers disrupt axonal
transport [12] and cause synapse deterioration, reversal of
spines, reduction of long-term potentiation (LTP), and
induction of long-term depression (LTD), as well as al-
tered mitochondrial distribution and dynamics in neurons
[13]. Inhibition of LTP [14] and reversal of LTD [15]
observed in the rat dentate gyrus are associated with im-
pairment of cognitive function. Binding of Aβ oligomers
to specific binding sites on neurons (reviewed in [16])
leads to redistribution of synaptic proteins and activation
of ionotropic glutamate receptors [17]. Aβ oligomers in-
hibit LTP by increasing N-methyl-D-aspartate (NMDA) re-
sponse through glutamate ionotropic receptor NMDA
type subunit 2B. Furthermore, these molecules may cause
a rapid depolarization of neurons and release of glutamate
due to Ca2+ entry, leading to excitotoxicity and synapse
loss [17].
Additionally, mutations in PSEN1, PSEN2, and APP
cause imbalances between synthesis and degradation of
Aβ. For instance, PSEN mutations lead to a partial loss
of function in the γ-secretase complex and consequently
to incomplete Aβ digestion [18], whereas most of the
mutations in APP have been found to increase produc-
tion of Aβ peptides [19]. The above-described gene aber-
rations result in many abnormal cellular responses, such
as mitochondrial dysfunction, inflammation, activation
of microglia, and neuronal loss [20].
The main mechanism in amyloid pathology in fAD is
the increased production of Aβ species, whereas de-
creased Aβ clearance is postulated in sAD, which is
modulated by the apolipoprotein E (APOE) genotype.
APOE isoforms differentially regulate Aβ aggregation
and clearance in the brain and have distinct functions in
regulating brain lipid transport, glucose metabolism,
neuronal signaling, neuroinflammation, and mitochon-
drial function (reviewed in [21]). There are at least three
alleles of the APOE gene—ε2, ε3, and ε4—coding differ-
ent isoforms of the protein. The most common allele
(~60% in the population) is ε3. Individuals carrying the
ε4 allele are at increased risk of AD compared with
those carrying the ε3 allele, whereas the ε2 allele is
known to decrease the risk.
The second characteristic of AD is TAU-based neuro-
fibrillary pathology. TAU is a microtubule-associated
protein (MAPT) required for stabilizing microtubules,
the major component of the neuronal cytoskeleton. This
protein is involved in neurite outgrowth, maintenance of
neuronal polarity, and axonal transport (reviewed in
[22]). Phosphorylation of TAU is regulated by kinases
and phosphatases, and their actions on TAU molecules
are required for proper neuronal growth. Site-specific
phosphorylation of TAU plays a crucial role in micro-
tubule stabilization, dynamic behavior, and spatial
organization of microtubules in neurons and axonal
transport regulation (reviewed in [23]).
In AD, hyperphosphorylated TAU (AD pTAU) spon-
taneously aggregates into paired helical filaments (PHFs)
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and form NFTs. Abnormal phosphorylation of TAU
impairs microtubule-binding capacity and leads to
microtubule destabilization [24]. These disturbances
may cause improper anterograde and retrograde axonal
transport and perturb intraneuronal signaling, including
synaptic transmission (reviewed in [25]).
TAU dysfunction is also related to other forms of de-
mentia, including frontotemporal lobar degeneration,
commonly referred as frontotemporal dementia (FTD),
which affects people before the age of 65 [26]. Mutations
in several different genes can cause FTD; however, the
granulin precursor (GRN) and MAPT genes are the most
frequent harborers of such mutations. This genetic alter-
ation induces TAU hyperphosphorylation and aberrant
NFT formation [27, 28].
Studies on normal human brain tissue have revealed
phosphorylation of TAU at several serine and threonine
residues, whereas in AD more than 40 different phos-
phorylation sites have been identified [29]. Most of the
sensitive TAU hyperphosphorylation sites are located at
the microtubule-binding repeat domain in the proline-
rich regions [30]. These regions include serine and
threonine residues in serine-proline and threonine-
proline motifs, and therefore they are targets of proline-
directed protein kinases such as glycogen synthase
kinase 3β (GSK3B) [31]. Studies have clearly demon-
strated that phosphorylation of TAU by GSK3B and
cyclin-dependent kinase 5 reduces the affinity of TAU to
bind to microtubules [31], whereas phosphorylation of
the serines within the KXGS motifs destructively affects
TAU-microtubule interactions [32]. Recent data have
shown that Aβ accumulated in the AD brain can activate
kinases that promote TAU phosphorylation, including
GSK3B [33]. GSK3B phosphorylates serine and threo-
nine residues in TAU PHFs, and its activity corresponds
with increased Aβ expression and Aβ-mediated neuronal
death. Additionally, active forms of GSK3B were ob-
served in cell lines with presenilin mutations [34].
Current understanding of AD pathogenesis is limited
owing to the difficulties in obtaining and culturing hu-
man brain tissue and live neurons and inability to model
the disease. The recently developed induced pluripotent
stem cell (iPSC) technology may provide a new platform
to create reliable human disease models for better un-
derstanding the pathological mechanisms of AD and for
establishment new therapeutic strategies. An increasing
number of studies have shown that neurons derived
from patient-specific iPSCs can recapitulate the major
cellular phenotypes of AD and hence may offer them-
selves for disease modeling or drug development [35]. In
regard to AD, a few research groups have reported ele-
vated levels of Aβ1–42 and increased Aβ1–42/Aβ1–40 ratio
in neurons differentiated from iPSCs of patients with
fAD [36–39], whereas authors of one report detected an
increased secretion of Aβ1–42 in only one patient with
sAD [40]. Additionally, AD neurons revealed elevated
phosphorylation of TAU at Thr231 as well as an in-
creased level of active GSK3B, and they accumulated
large RAB5A-positive early endosomes [40].
We report the generation and neural differentiation of
iPSCs derived from several patients with fAD and sAD,
as well as from control individuals without dementia.
The aim of our present study was to establish an in vitro
cellular model that reveals major phenotypes of AD and
enables investigation of the pathomechanisms of late-
onset AD. Amyloid-β (Aβ) production, TAU phos-
phorylation, and GSK3B activation were investigated in
all lines. Moreover, cellular responses to extracellular
hydrogen peroxide and Aβ1–42 oligomers were analyzed
in control and AD-derived neural cells. We demonstrate
that both fAD and sAD pathology can be recapitulated
and that TAU pathology can be investigated in an iPSC-
based in vitro human cellular model.
Methods
The chemicals used were purchased from Sigma-Aldrich
(St. Louis, MO, USA), and the cell culture reagents and
culture plates were purchased from Thermo Fisher
Scientific (Waltham, MA, USA), unless specified otherwise.
iPSC lines
iPSC lines derived from patients with AD used in this
study were characterized and published earlier [41–46],
as detailed in Table 1. The patients were clinically diag-
nosed and characterized by the Institute of Genomic
Medicine and Rare Disorders, Semmelweis University,
Budapest, Hungary, or at the Danish Dementia Research
Centre, Rigshospitalet, University of Copenhagen, as
described previously. Volunteers without dementia
(assessed by clinical evaluation) were used as control
subjects, from whom iPSC lines were established,
characterized, and maintained under identical conditions
as the AD iPSC lines. The hiPSC lines were maintained
on Matrigel (BD Matrigel; STEMCELL Technologies,
Vancouver, BC, Canada) in mTESR1 (STEMCELL
Technologies) culture media. The media were changed daily,
and the cells were passaged every 5–7 days using Gentle
Cell Dissociation Reagent (STEMCELL Technologies) ac-
cording to the manufacturer’s instructions.
Neural induction of iPSCs
Neural progenitor cells (NPCs) were generated from
each of the human iPSCs by dual inhibition of SMAD
signaling pathway using LDN193189 and SB431542 [47].
Neural induction was initiated upon reaching a desired
confluence of iPSCs on Matrigel-coated dishes by
addition of neural induction medium (NIM) (1:1 vol/vol
mixture of DMEM/F12 and neurobasal medium, 1× N-2
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supplement, 1× B-27 supplement, 1× nonessential amino
acids [NEAA], 2 mM L-glutamine, 50 U/ml penicillin/
streptomycin, 100 μM β-mercaptoethanol, 5 μg/ml
insulin), which was supplemented with 5 ng/ml basic
fibroblast growth factor (bFGF), 0.2 μM LDN193189
(Selleckchem, Houston, TX, USA), and 10 μM
SB431542. The NIM was changed every day. At day 10,
neural rosettes were picked manually, replated on poly-
L-ornithine/laminin (POL/L) (Sigma-Aldrich)-coated
dishes, and expanded in neural maintenance medium
(NMM) (1:1 vol/vol mixture of DMEM/F12 and neuro-
basal medium, 1× N-2 supplement, 1× B-27 supplement,
1× NEAA, 2 mM L-glutamine, 50 U/ml penicillin/
streptomycin), and supplemented with 10 ng/ml epider-
mal growth factor and 10 ng/ml bFGF.
Neural differentiation of NPCs
To generate human neurons, NPCs were plated on the
POL/L-coated dishes and cultured in neural differenti-
ation medium (1:1 vol/vol mixture of DMEM/F12 and
neurobasal-A medium, 1× N-2 supplement, 1× B-27
supplement, 1× NEAA, 2 mM L-glutamine, 50 U/ml
penicillin/streptomycin) supplemented with 0.2 mM as-
corbic acid and 25 μM β-mercaptoethanol. For terminal
differentiation (TD) into cortical neurons, the cells were
plated on POL/L (0.002%/2 μg/cm2) at a seeding density
of 40,000 cells/cm2 for immunocytochemistry (ICC) and
100,000 cells/cm2 for enzyme-linked immunosorbent
assay (ELISA) and Western blotting experiments with
NMM. The medium was changed every 3–4 days during
the course of TD. The efficiency of TD was monitored
by ICC staining and RT-qPCR for tubulin-β 3 class III
(TUBB3) and microtubule-associated protein 2 (MAP2)
expression at week 10. In the present study, NPCs from
passage 9 to passage 10 were differentiated up to
10 weeks for ELISA and Western blotting experiments,
whereas samples were collected at weekly intervals.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde (PFA) for
20 minutes at room temperature (RT), washed twice
with PBS, and permeabilized with 0.2% Triton X-100 in
PBS for 20 minutes. Then, cells were blocked with 3%
bovine serum albumin (BSA) in the presence of 0.2%
Triton X-100 in PBS for 60 minutes at RT. The
respective primary antibodies were applied overnight at
4 °C (Additional file 1: Table S1). To detect the signal,
cells were incubated for 60 minutes at RT with the
appropriate secondary antibodies (Alexa Fluor 488 don-
key anti-rabbit immunoglobulin G [IgG] [H + L], Alexa
Fluor 594 donkey anti-mouse IgG [H + L], Alexa Fluor
488 donkey anti-mouse IgG [H + L], or Alexa Fluor 594
donkey anti-rabbit IgG [H + L]; Life Technologies,
Carlsbad, CA, USA). Cell nuclei were visualized using
VECTASHIELD Mounting Medium with 4′,6-diamidino-
2-phenylindole (1.5 μg/ml; Vector Laboratories,
Burlingame, CA, USA). Cells were analyzed under a
fluorescence microscope equipped with a 3D imaging
module (Axio Imager system with ApoTome; Carl Zeiss
MicroImaging GmbH, Göttingen, Germany) controlled
using AxioVision 4.8.1 software (Carl Zeiss MicroImaging
GmbH).
Electron microscopy
To evaluate the neuronal cultures, a monolayer of
5-week-old neurons grown on POL/L-treated glass cov-
erslips was fixed with a fixative solution containing 3.2%
PFA, 0.2% glutaraldehyde, 1% sucrose, and 40 mM CaCl2
Table 1 Cell lines used in this study
iPSC line name Clone number Identifier in the study Disease Mutation Sex Reference
BIOT-7183-PSEN1 S1 fAD-1 Early-onset fAD PSEN1 c.265G>C, p.V89L F [41]
S2 fAD-2
H234 C5 fAD-3 Early-onset fAD PSEN1 c.449T>C, p.L150P M [42]
H235 C6 fAD-4 Early-onset fAD PSEN1 c.449T>C, p.L150P M –
BIOT-0904-LOAD S2 sAD-1 Late-onset sAD Unknown M [43]
S3 sAD-2
BIOT-0630-LOAD S4 sAD-3 Late-onset sAD Unknown F [44]
BIOT-4828-LOAD S1 sAD-4 Late-onset sAD Unknown F [45]
S6 sAD-5
BIOT-0726-LOAD S3 sAD-6 Late-onset sAD Unknown F [46]
CTRL1 S9 Ctrl-1 Healthy – F –
S11 Ctrl-2
H250 C16 Ctrl-3 Healthy – F –
H256 C6 Ctrl-4 Healthy – M –
Abbreviations: iPSC Induced pluripotent stem cell, LOAD Late-onset Alzheimer’s disease
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in 0.1 M cacodylate buffer for 24 h at 4 °C. Samples were
rinsed for 2 days in cacodylate buffer, then postfixed in 1%
ferrocyanide-reduced osmium tetroxide [48] for 1 h at RT.
The samples were then treated with aqueous 1% uranyl-
acetate for 30 minutes and embedded in Spurr low-
viscosity epoxy resin medium (Sigma-Aldrich) according
to the manufacturer’s instructions and cured for 24 h at
80 °C. Ultrathin sections were stained with Reynolds lead
citrate for 2 minutes and examined under a JEOL JEM
1011 transmission electron microscope (JEOL, Peabody,
MA, USA) operating at 60 kV. Photographs were taken
using an Olympus Morada 11-megapixel camera and
iTEM software (Olympus, Center Valley, PA, USA).
Flow cytometry
NPCs growing on POL/L-coated dishes were dissociated
into single cells with Accutase (Sigma-Aldrich) and fixed
with 4% PFA for 20 minutes at RT. Cells were perme-
abilized with 0.2% Triton X-100 in PBS for 5 minutes at
RT and blocked with 10% FBS in PBS for 20 minutes at
RT. Cells were stained for 1 h at RT with Alexa Fluor
647 mouse anti-Nestin and phycoerythrin mouse anti-
human paired box 6 (PAX6) antibodies (BD Pharmingen,
San Jose, CA, USA). Flow cytometric analysis was
performed using a Cytomics FC 500 flow cytometer
(Beckman Coulter, Brea, CA, USA). To detect Nestin
(NES) and PAX6 expression in NPCs, an argon laser
(488 nm) and a red solid laser (635 nm), respectively,
were used. Flow cytometric data analysis was performed
using FlowJo software (version 7.6.5; FlowJo, LLC,
Ashland, OR, USA).
Immunoblotting
The cell cultures were lysed with RIPA Lysis and
Extraction Buffer supplemented with Halt™ Protease and
Phosphatase Inhibitor Cocktail and Pierce™ Universal
Nuclease for Cell Lysis (all from Thermo Fisher
Scientific). The protein extracts were derived from one
well of a six-well plate of a single neuronal differenti-
ation. Lysed samples were sonicated and incubated for
60 minutes on ice. Total protein concentration was
determined using a Pierce BCA Protein Assay Kit. Cell
lysates (2 μg) were separated on 10% sodium dodecyl
sulfate-polyacrylamide gel and transferred to Immun-Blot®
PVDF Membrane (Bio-Rad Laboratories, Hercules, CA,
USA). The membranes were blocked with Tris-buffered
saline with Tween 20 (TBST; 20 mM Tris-HCl, pH 7.4,
150 mM NaCl, 0.1% Tween 20) containing 5% BSA and
then incubated with the respective primary antibody solu-
tion overnight at 4 °C (Additional file 1: Table S1). After
being washed with TBST, the membranes were incubated
with horseradish peroxidase-conjugated secondary anti-
bodies for 1 h at RT. All the secondary antibodies were
either goat anti-mouse or goat anti-rabbit (Sigma-Aldrich).
All samples were analyzed at days 14, 28, 42, 56, and 70 of
TD, and the amount of pTAU and pSer9GSK3B relative to
total TAU and GSK3B in lysates was measured. Signals
were detected with SuperSignal™ West Dura Extended
Duration Substrate by KODAK Gel Logic 1500 Imaging
System (Bruker, Billerica, MA, USA) and Kodak MI SE im-
aging software (Carestream, Atlanta, GA, USA). Densito-
metric measurement of protein band intensity was carried
out using Image Studio™ Lite software (LI-COR Biosci-
ences, Lincoln, NE, USA). Phosphorylation of TAU and
GSK3B protein was calculated from densitometric data of
phosphoproteins divided by densitometric data of nonpho-
sphorylated proteins.
Measurement of Aβ1–40 and Aβ1–42 by ELISA
Conditioned medium was collected after 4 days of cul-
ture (without media change) at every week from one
well of a six-well plate. To prevent protein degradation,
4-(2-aminomethyl)benzenesulfonyl fluoride hydrochlor-
ide was added to the medium. Extracellular Aβ1–40 and
Aβ1–42 levels were measured using the Human β-
Amyloid (1-40) ELISA Kit and Human β-Amyloid (1-42)
ELISA Kit (Wako Chemicals, Neuss, Germany) accord-
ing to the manufacturer’s instructions. The secreted Aβ
levels determined (in picomolar concentrations) were
normalized to total protein content of cell lysate. The
signal was detected using a Varioskan Flash multimode
reader (Thermo Fisher Scientific).
As a control value we used the average value (±SEM)
of the four clones derived from healthy individuals
(ctrl-1, ctrl-2, ctrl-3, ctrl-4) in all experiments. The indi-
vidual expression levels are presented in Additional file 2:
Figure S1.
RT-qPCR
Total RNA was isolated from differentiated neurons at
different time points using the RNeasy Plus Mini Kit
(QIAGEN, Valencia, CA, USA) according to the
manufacturer’s protocol. One microgram of RNA was
transcribed using the SuperScript™ III VILO™ cDNA
Synthesis Kit (Thermo Fisher Scientific). The PCR
conditions were subjected to 94 °C for 3 minutes as an
initial denaturation step, followed by 40 cycles of 95 °C
for 5 seconds for denaturation, 60 °C for 15 seconds for
annealing, and 72 °C for 30 seconds for elongation. The
amplification reactions were carried out in a total
volume of 15 μl using SYBR Green JumpStart Taq
ReadyMix (Sigma-Aldrich). RT-qPCR was run on the
Rotor-Gene Q 5plex Platform (QIAGEN) using
oligonucleotide primers detailed in Additional file 3:
Table S2. Human glyceraldehyde 3-phosphate dehydro-
genase GAPDH) was used as a reference gene. The data
were analyzed using REST software (2009; version 2.0.13).
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Library preparation and next-generation sequencing
Genomic DNA (gDNA) was isolated from peripheral blood
mononuclear cells using the GenElute Mammalian
Genomic DNA Miniprep Kit (Sigma-Aldrich). An
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA) was used to determine the concen-
tration and purity of the isolated gDNA. The gDNA integ-
rity was evaluated by 0.8% agarose gel electrophoresis.
The multiplexed library preparation was performed by
using the SureSelectQXT and SureSelectXT Human All
Exon V6 Target Enrichment systems according to the
manufacturer’s instructions (Agilent Technologies, Santa
Clara, CA, USA). The probe set targeted > 99% of RefSeq
(~20,000) genes with a total target size of 60 Mb. Pooled
libraries were sequenced on the NextSeq 500 platform
(Illumina, San Diego, CA, USA) in a 2 × 80-bp paired-
end run. The average throughput was > 80 million reads
(4 Gbp per sample). Primary data analysis, filtering, and
adapter trimming were performed using NextSeq
Control Software (version 1.4.1; Illumina). Alignment
was done using the Burrows-Wheeler Aligner (Illumina)
[49] to the GRCh37/hg19 reference genome, and variant
calling was performed with the Genome Analysis Toolkit
(GATK) [50]. Variants were annotated using the
wANNOVAR web server [51, 52], and their phenotypic
effects were evaluated using the American College of
Medical Genetics and Genomics standards and guide-
lines [53].
Cell viability assay after H2O2 and Aβ treatment
Neurons growing on a 96-well plate at days 28 and 56 of
TD were treated with 30 μM and 60 μM of hydrogen
peroxide (H2O2) (Sigma-Aldrich) or 5 μM Aβ1–42
oligomer solution. For preparation of oligomer solution,
iso-Aβ1–42 peptides were used as detailed elsewhere [54]
(provided by University of Szeged, Hungary). Viability of
the cultures following H2O2 and Aβ treatment was
assessed at 24 h of stimulation using a CellTiter-Glo®
Luminescent Cell Viability Assay (Promega, Madison,
WI, USA). The luminescent signal was detected using
the Varioskan Flash Multimode Reader. Neuronal sur-
vival was represented as a percentage of control.
Statistical analysis
All results were analyzed using Prism 5 (GraphPad
Software, La Jolla, CA, USA) and Microsoft Office 2010
(Microsoft, Redmond, WA, USA) software. All data on
the graphs represent the average of the triplicate mea-
surements (n = 3). The “n” value corresponds to the
number of replicates for each cell line. Analysis of data
is presented as the mean ± SEM. Dunnett’s method was
used to compare the individual groups with control sub-
jects. In all cases, significance was noted at p < 0.05.
Results
Neuronal differentiation capacity of iPSCs derived from
patients with fAD and patients with sAD is similar
Samples from patients with fAD and patients with sAD
were reprogrammed, and iPSC lines were generated and
characterized by our teams as previously reported [41–46].
In the present study, we studied iPSC clones derived from
three patients with fAD with mutation in PSEN1
(contributing with in total four lines: fAD-1, fAD-2, fAD-3,
fAD-4), four patients with late-onset sAD (contributing
with in total six lines: sAD-1, sAD-2, sAD-3, sAD-4,
sAD-5, sAD-6), and three individuals without dementia
as control subjects (contributing with in total four lines:
ctrl-1, ctrl-2, ctrl-3, ctrl-4) (see also Table 1). In all sAD
samples, next generation sequencing analysis revealed a
lack of pathogenic mutations in APP, PSEN1, and PSEN2,
indicating late-onset AD. Moreover, sequencing of
MAPT and GRN excluded FTD as well. The APOE
status of the cell lines included in the study is shown
in Additional file 4: Table S3.
All AD iPSCs and control iPSCs were successfully
converted into neuronal progenitor cells (NPCs) and
expressed neuroepithelial markers PAX6 and NES (Fig. 1a).
To quantify the efficiency of NPC formation, flow cytome-
try was applied, which showed that there were no signifi-
cant differences between any of the cell lines with respect
to generating NPCs including > 70% copositivity for PAX6
and NES (Fig. 1b).
Next, the neuronal differentiation of fAD and sAD
NPCs was investigated and compared with that of con-
trol lines at different time points (TD14, TD28, TD42,
TD56, TD70). ICC labeling showed that the increasing
expression of neuronal markers TUBB3 and MAP2 dur-
ing neuronal differentiation was comparable among AD
and control cell lines (Fig. 2a). More mature marker-
s—TAU and neurofilament, heavy polypeptide 200 kDa
(NF200)—appeared later during differentiation than
MAP2 and TUBB3 (Fig. 2a). ICC analysis at day 70 of
AD and control neural cultures revealed the presence of
proteins related to distinct subtypes of mature neurons:
markers of cholinergic neurons (vesicular acetylcholine
transporter [VACHT]), dopaminergic neurons (tyrosine
hydroxylase [TH]), GABAergic (glutamic acid decarbox-
ylases 2 and 1 [GAD2/GAD1]), and glutamatergic neu-
rons (vesicular glutamate transporter 1/2 [VGLUT1/2])
(Fig. 2b). In order to compare gene expression levels,
RT-qPCR was performed on day 70 neurons. The ana-
lysis revealed that the AD and control lines expressed
comparable levels of MAP2, sodium-dependent sero-
tonin transporter (SLC6A4), NMDA receptor subunit
NR1 (glutamate ionotropic receptor N-methyl-D-as-
partate type subunit 1 [GRIN1]), marker of maturing neu-
rons – RNA binding protein, fox-1 homolog 3 (RBFOX3),
and GAD1 (Fig. 2c). Moreover, they also showed high
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expression levels of dopaminergic neuron marker (TH),
astrocyte marker (glial fibrillary acidic protein [GFAP]),
and an early oligodendrocyte marker (claudin 11
[CLDN11]) (Fig. 2c). Furthermore, the cells expressed
TUBB3, choline O-acetyltransferase (CHAT), and postsyn-
aptic density protein 95 (discs large MAGUK scaffold pro-
tein 4 [DLG4]). Importantly, no evident differences in
gene expression levels were observed between control,
fAD, and sAD lines. Additionally, electron microscopy of
neural cell cultures at day 35 revealed the presence of
synapses with docking of synaptic vesicles and synaptic
clefts (Fig. 2d). These findings indicate that AD has no sig-
nificant effect on the overall neural differentiation of
iPSCs in the used system, as well as that NPCs can be dif-
ferentiated into various neuronal and glial cell types with
similar efficiency independent of their origin from patients
with AD or healthy individuals.
Elevated level of Aβ was secreted by fAD and sAD
neurons
To determine Aβ production from iPSC lines of patients
with fAD and patients with sAD, secreted Aβ1–40 and
Aβ1–42 levels were measured weekly by ELISA in the
conditioned media of differentiated neural cell lines from
the second to tenth weeks of differentiation. Elevated
secreted Aβ1–40 and highly increased Aβ1–42 levels were
Fig. 1 Immunofluorescence characterization of the induced pluripotent stem cells (iPSCs) derived neural progenitor cells. a Representative images
of neural progenitor cells (NPCs) from healthy control individuals (ctrl-1–ctrl-4), patients with early-onset familial Alzheimer’s disease (fAD-1–fAD-4), and
patients with late-onset sporadic Alzheimer’s disease (sAD-1–sAD-6) stained with Nestin (green), paired box 6 (PAX6; red), and 4′,6-diamidino-2-phenylindole
(DAPI; blue). All three groups exhibited similar progenitor marker expression. scale bar = 30 μm. b Flow cytometric analysis of cultured NPCs. Dot plots
demonstrate similar expression pattern of PAX6 and Nestin in control, fAD, and sAD iPSC line-derived NPC cultures with similar passage numbers (p6)
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observed in all fAD neural cultures compared with the
mean level in the control lines at almost all time points
(Fig. 3). The Aβ1–42/Aβ1–40 ratio was also increased up
to twofold for the fAD-iPSC-derived neurons. The extra-
cellular level of Aβ1–40 in all sAD neurons was signifi-
cantly higher than in control and fAD neurons. The
Aβ1–42 secretion in sAD neurons was also elevated com-
pared with the average values of the control neurons;
however, the levels did not reach the same levels as in
fAD neurons. Interestingly, the measured Aβ1–42/Aβ1–40
ratio in all sAD-iPSC-derived neurons was similar to that
in control neurons (Fig. 3c). In nonmature neurons up to
day 14 (TD14), Aβ production was comparable among
AD and control lines (Additional file 2: Figure S1). During
neural differentiation, Aβ1–40 and Aβ1–42 levels gradually
increased to reach the investigated maximum at day 70 of
Fig. 2 Neuronal differentiation from control and Alzheimer’s disease induced pluripotent stem cells (AD-iPSCs). a Representative immunofluorescence
images show expression of neuronal markers at day 70 of terminal differentiation (TD70): tubulin β 3 class III (TUBB3; green, left panel), microtubule-associated
protein 2 (MAP2; red, left panel), TAU (red, middle panel), and neurofilament, heavy polypeptide 200 kDa (NF200; red, right panel). Scale bar = 50 μm.
b Differentiation of iPSCs into various neuronal subtypes at TD70 was confirmed by the presence of specific markers: vesicular acetylcholine transporter
(VACHT) (cholinergic neurons), glutamic acid decarboxylases 2 and 1 (GAD2/1) (GABAergic neurons), TH (dopaminergic neurons), and vesicular
glutamate transporter 1/2 (VGLUT1/2) (glutamatergic neurons). Scale bars = 40 μm and 10 μm as indicated. c Gene expression of neuronal markers
from ctr-1, early-onset familial Alzheimer’s disease (fAD-1), and sporadic Alzheimer’s disease (sAD-1) lines at TD70 obtained by qPCR. The expression
values were normalized to GAPDH and calculated as a relative amount of messenger RNA versus expression value of neural progenitor cells, which
was set to 1. Data are reported as mean ± SEM of three independent measurements. AD-iPSC neurons demonstrate expression pattern similar to
that of neuronal cells derived from control iPSCs. d Ultrastructure of a synapse at TD35 with synaptic vesicles (Sv) and synaptic cleft with synaptic
junctions (tight junctions, black arrowheads). Docking synaptic vesicles are also observable (white arrowheads). Scale bar = 100 nm.
DAPI 4′,6-Diamidino-2-phenylindole
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TD (endpoint of experiment; TD70), suggesting a
maturation-dependent secretion of Aβ (Fig. 3, Additional
file 2: Figure S1). The results at TD14 and TD28 indicated
a transition period in which not all AD samples showed
significant differences from the control samples, but from
TD42, all AD samples displayed elevated amounts of Aβ.
Therefore, we concentrated our further experimental ana-
lyses on the samples matured for a minimum of 6 weeks.
To evaluate the level of APP, the direct precursor of
Aβ in neurons, we performed Western blot analysis. The
results revealed that APP expression increased during
neuronal differentiation and reached a maximum at day
70 (TD70) in all fAD and sAD neural cultures (Fig. 4,
Additional file 5: Figure S2a). Expression of this protein
was significantly increased in all AD cell lines from
TD42. Subsequently, we quantified the amount of
amyloid precursor protein carboxy-terminal fragment
(APP-CTF) generated through APP cleavage by β-secretase.
As shown in Fig. 4 and Additional file 5: Figure S2b, re-
markably higher APP-CTF protein levels were detected in
fAD and sAD neurons. No significant differences in the ex-
pression of APP and APP-CTF were observed between
fAD and sAD neurons. In summary, both Aβ and APP
levels were significantly elevated in fAD and sAD neural
cultures compared with control cultures. These differences
were detectable after 6 weeks (TD42) but were prominent
with all sAD lines at week 10 (TD70).
Epitope-specific TAU hyperphosphorylation was detected
in fAD and sAD lines
One of the proposed mechanisms for the TAU protein
pathomechanism in AD are posttranslational modifications
through abnormal phosphorylation (hyperphosphorylation)
(reviewed in [55]). The appearance and accumulation of
abnormally phosphorylated TAU leads to mislocalization
and aggregation of TAU as well as formation of NFTs [56].
Therefore, we focused on the alterations of TAU phosphor-
ylation in our fAD and sAD neural cultures. TAU protein
contains several phosphorylation sites (reviewed in [57]).
Fig. 3 Characterization of amyloid-β (Aβ) secretion in control and
Alzheimer’s disease induced pluripotent stem cell (AD iPSC)-derived
neurons at terminal differentiation day 42 (TD42), TD56, and TD70.
a The amount of secreted Aβ1–40 from control-, early-onset familial
Alzheimer’s disease (fAD)- (fAD-1–fAD-4), and sporadic Alzheimer’s
disease (sAD)- (sAD-1–sAD-6)-iPSC-derived neurons. b The amount
of Aβ1–42 released from control- and AD-iPSC-derived neurons. c The
ratio of Aβ1–42/Aβ1–40 from neurons derived from control and AD
lines. Aβ1–40 and Aβ1–42 secreted from neural cells into the medium
were measured at day 4 after the last medium change. The extracellular
Aβ levels determined (in picomolar concentrations) were normalized to
total protein content of cell lysates. Data represent mean ± SEM
(n = 3). Dunnett’s test was performed to evaluate the significance
of groups compared with control at the same time point of
differentiation (*p < 0.05)
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We examined six different phosphorylation sites (Fig. 5a)
in fAD, sAD, and control neural cultures at different time
points of TD. We observed significantly higher phosphor-
ylation of TAU at Ser262 (12E8 epitope) in all our AD neu-
rons than in control neurons (Fig. 5b, Additional file 6:
Figure S3a). Elevated phosphorylation was detected already
at TD42 and reached the highest level between weeks 8
and 10 (TD56 and TD70) of TD. Further analysis revealed
upregulated TAU phosphorylation at the Ser396 epitope in
all fAD and sAD neural cultures (Fig. 5c, Additional file 6:
Figure S3b). Western blot quantification showed an in-
crease in TAU phosphorylation at Ser202/Thr205 (AT8
epitope) in the AD group (Fig. 5d, Additional file 6:
Figure S3c). Furthermore, we observed higher phos-
phorylation of TAU at Thr181 and Ser400/Thr403/
Ser404 in both fAD and sAD neurons (Fig. 5e and f,
Additional file 6: Figure S3d and e). On the basis of
these results, we can conclude that, although the phos-
phorylation level showed some clonal variations, the ra-
tio of pTAU/TAU was significantly elevated in all AD
neurons and that no major differences were observed
between fAD- and sAD-derived neurons.
GSK3B activation in AD-derived neurons
Scientific evidence suggests that GSK3B is involved in
many pathological hallmarks of AD, including hyperpho-
sphorylation of TAU [58], increased Aβ production [59],
memory impairment, and neuronal loss [60]. To verify if
AD neurons with elevated TAU phosphorylation have
increased GSK3B activity, the percentage of the active
form of GSK3B was calculated by assessing the ratio of
inhibitory phosphorylation on Ser9 by immunoblotting.
Our results demonstrate that fAD and sAD neurons in
most cases exhibited significantly higher levels of active
GSK3B than control neurons (Fig. 6a–c, Additional file 7:
Figure S4a). During neuronal differentiation, the level of
active GSK3B in control neurons remained constant,
whereas in fAD and sAD neurons, the active GSK3B
amount increased to reach its maximum at day 56
(sAD-2) or day 70 of TD for all remaining cell lines
(Fig. 6c, Additional file 7: Figure S4a). Furthermore, higher
phosphorylation of TAU at Thr231 (AT180 epitope),
which can be catalyzed by GSK3B in vitro [61], was
observed in all fAD and sAD neurons (Fig. 6d, Additional
file 7: Figure S4b). These results indicate that activation of
Fig. 4 Characterization of amyloid precursor protein (APP) and amyloid precursor protein carboxy-terminal fragment (APP-CTF) expression during
neuronal differentiation. Representative immunoblots of (a) APP and APP-CTF in control neurons (ctrl-1), early-onset familial Alzheimer’s disease
(fAD)-derived neurons (fAD-1–fAD-4), and (b) sporadic Alzheimer’s disease (sAD)-derived neurons (sAD-1–sAD-6) at terminal differentiation day 14
(TD14), TD28, TD42, TD56, and TD70. Quantification of (c) APP and (d) APP-CTF signals at TD70 was normalized to GAPDH. Data are presented as
mean ± SEM (n = 3). Dunnett’s test was performed to evaluate the significance of groups compared with control (*p < 0.05)
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Fig. 5 (See legend on next page.)
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the GSK3B signaling in both fAD and sAD neurons con-
tributes to the abnormal TAU phosphorylation pattern
observed in these cell lines.
Oxidative stress response was strongly affected in fAD
and sAD neuronal cultures
Oxidative stress plays an important role in the pathogen-
esis of neurodegenerative disorders. The molecular
mechanism of reactive oxygen species (ROS) action in
the nervous system has been studied ([62, 63], reviewed
in [64]). Despite this, the effect of oxidative stress on hu-
man iPSC-derived AD neurons is still not well studied.
In our experiments, we used H2O2 in two different con-
centrations to examine neuronal response to a stressor.
In AD and control neurons, treatment with increasing
doses of H2O2 engendered a dose-dependent loss of cell
viability; however, these two cell groups presented differ-
ential susceptibility to the stressor. The fAD and sAD
neurons were more sensitive than control neurons to
H2O2, and cell death caused by 30 μM and 60 μM H2O2
(See figure on previous page.)
Fig. 5 Western blot analysis of total TAU and phosphorylated TAU (pTAU) protein. a Schematic representation of human TAU isoform (441 amino
acids) with the functional projection and microtubule-binding domains. Projection domains including a proline-rich region and N-terminal part
interact with cytoskeletal elements and are involved in signal transduction. Microtubule-binding domains with a C-terminal part regulate the
microtubule polymerization and bind to proteins such as presenilin 1 (PSEN1). Epitopes of pTAU antibodies analyzed in this study are indicated
on the scheme. b–f Densitometric analysis of TAU phosphorylated at different epitopes: S262, S396, S202/T205, T181, and S400/T403/S404. All
samples were analyzed at day 70 of terminal differentiation. The amount of pTAU relative to total TAU levels in the lysates was measured. GAPDH
as the loading control was used to normalize the data. All values are the mean ± SEM (n = 3). Dunnett’s test was performed to evaluate the
significance of groups compared with control (*p < 0.05)
Fig. 6 Analysis of glycogen synthase kinase 3β (GSK3B) and the active form of GSK3B in neuronal culture. a Representative immunoblotting shows the
phosphorylation of GSK3B at Ser9 (inactive form of the kinase [102]) and GSK3B in control neurons (ctrl-1), early-onset familial Alzheimer’s disease (fAD)
neurons (fAD-1–fAD-4), and (b) sporadic Alzheimer’s disease (sAD) neurons (sAD-1–sAD-6) at all time points of neuronal terminal differentiation
(TD14–TD70). c Quantification of the active GSK3B form at TD70 was presented as a percentage of nonphosphorylated GSK3B at Ser9. d Densitometric
analysis of TAU phosphorylated at the T231 epitope at TD70. All values were normalized to GAPDH and are presented as mean ± SEM (n = 3). Dunnett’s
test was performed to evaluate the significance of groups compared with control (*p < 0.05)
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reached about 50% and 70%, respectively, in the AD cul-
tures (Fig. 7a).
Evidence of the toxicity of Aβ to neurons has been
demonstrated in rodent models and neuronal cell lines
(reviewed in [65, 66]). Owing to the limited studies on
neurons generated from iPSCs, we examined the effect
of synthetic Aβ1–42 oligomer solution on iPSC-derived
neurons. Cells treated at days 28 and 56 of neural differ-
entiation for 24 h with 5 μM Aβ1–42 oligomers showed
reduced neuronal survival, depending on the neuronal
maturation state (Fig. 7b). Relative to control samples,
AD cultures had enhanced sensitivity to cell toxicity in-
duced by Aβ1–42. The 28-day-old AD neurons displayed
about 15–20% cell death compared with 10% cell loss in
control individuals. Mature neurons at TD56 were more
susceptible to cell death; almost 40% of neurons died in
AD cultures, whereas cell loss in control neurons in-
creased slightly to 15% (Fig. 7b). On the basis of our re-
sults, we can conclude that fAD and sAD neural
cultures are more susceptible to Aβ1–42 oligomer-
induced cell death than the control cultures.
Discussion
The present study shows that particular key disease phe-
notypes of the most common age-related neurological
disorder, AD, can be modeled using patient-specific,
Fig. 7 Effect of hydrogen peroxide (H2O2) and amyloid-β1–42 (Aβ1–42) oligomer treatment on neuronal viability. a Viability of induced pluripotent
stem cell (iPSC)-derived neurons from control individuals (ctrl-1–ctrl-4), patients with early-onset familial Alzheimer’s disease (fAD) (fAD-1–fAD-4),
and patients with sporadic Alzheimer’s disease (sAD) (sAD-1–sAD-6) at day 28 of terminal differentiation (TD28) and TD56 after 24 h of treatment
with 30 μM H2O2 (left panel) and 60 μM H2O2 (right panel). b Neuronal survival of control and Alzheimer’s disease (AD) clones at TD28 and TD56
cultured 24 h in the presence of 5 μM Aβ1–42 oligomer solution. Neuronal survival was represented as a percentage of control. Viability of the
cultures following H2O2 and Aβ treatment was assessed using the CellTiter-Glo® Luminescent Cell Viability Assay. Values are presented as the
mean ± SEM (n = 3). Dunnett’s test was performed to evaluate the significance of groups compared with control at the same time point of
differentiation (*p < 0.05)
Ochalek et al. Alzheimer's Research & Therapy  (2017) 9:90 Page 13 of 19
iPSC-derived neural cells. Over the past few decades,
primary neurons from animal models and immortalized
neuronal cell lines have been used to study neurode-
generative diseases. Owing to many limitations, such as
genetic and physiological differences between human and
rodent brains, such studies of AD mechanisms have been
controversial. Most animal models of AD are generated
on the basis of modifications in three genes related to fAD
(APP, PSEN1, and PSEN2), whereas modeling of sAD in
rodents is currently not well examined. Therefore, there
are huge expectations regarding iPSC technology, which
allows for the generation of pluripotent cells from any
individuals in the context of their own genetic identity, to
provide new patient-specific in vitro disease models to
study neurological disorders.
Modeling AD using iPSCs was initiated with fAD car-
rying mutations in PSEN1, PSEN2, and APP. Until now,
only a few groups have reported generation of iPSC-
derived neurons from patients with fAD, and sAD has
been studied even less [36, 37, 40, 67]. In our present
study, we analyzed samples and generated neurons from
patients with fAD carrying pathogenic mutations in the
PSEN1 gene (V89L and L150P; these mutations were
first identified by Queralt et al. [68] and Wallon et al.
[69], respectively) and patients with sAD (Table 1). Our
findings demonstrate that iPSCs derived from patients
with fAD and patients with sAD can be successfully in-
duced into NPCs with very uniform expression of NES
and PAX6 and that they can be further differentiated
into neurons and glial cells. Gene expression and ICC
analysis revealed the presence of various neuronal sub-
types, including GABAergic, glutamatergic, cholinergic,
and dopaminergic neurons and progenitor cells of astro-
cytes and oligodendrocytes in control and AD cultures.
We therefore conclude that there is no prominent
difference in the differentiation and maturation propen-
sity or in marker gene expression between control and
AD neural cells, which is in accordance with a previous
report [37].
Initially, our main question was to evaluate if sAD can
be modeled through iPSC-derived neural cultures and
represent a suitable model system for neuropathological
investigations and drug development studies. Therefore,
we first analyzed the relevant in vivo pathological
hallmarks of the disease in our in vitro system. The ac-
cumulation of Aβ into extracellular aggregates is one of
the pathological signs of AD in the human brain. Alter-
ations in the level of Aβ peptides are often presented as
the ratios between different isoforms. In PSEN mutant
mouse models, elevated Aβ production can be detected
[70–72]. In humans, elevated Aβ production was re-
vealed in iPSC-derived neural lines from patients with
fAD [36]. However, another study demonstrated that Aβ
secretion in sAD-derived neurons is not consistently
altered [37]. Our study demonstrated increased extracel-
lular Aβ1–40 and Aβ1–42 levels in neurons derived from
all fAD and sAD lines in a maturation-dependent man-
ner. Interestingly, Aβ1–40 secretion was approximately
twofold higher in sAD neurons than in fAD, whereas
Aβ1–42 levels were similar. Moreover, we observed an
elevated ratio of Aβ1–42 to Aβ1–40, one of the AD hall-
marks, in fAD-derived neurons, whereas the Aβ1–42/
Aβ1–40 ratio in sAD lines remained unchanged and com-
parable to that of non-AD control lines. Additionally, we
observed upregulated expression of APP and APP-CTF
in all AD-derived cell lines, which is in line with the in-
creased Aβ levels we measured. Some groups also de-
tected an increased level of Aβ1–40, Aβ1–42, and Aβ1–42/
Aβ1–40 ratio in fAD cell lines with mutations in PSEN1,
PSEN2, and APP [36, 37, 40]. On the basis of the above
results, we can conclude that mutations in PSEN1 may
change the metabolism of Aβ peptides and drive amyl-
oidosis in patients with fAD. Our findings also indicate
the possible heterogeneity of fAD and sAD. AD-iPSC
lines with PSEN1 mutations and sAD do not always re-
capitulate the same phenotypes [37]. In fAD, genetic fac-
tors modify the clinical phenotype of the disease,
whereas mechanisms underlying the pathogenesis of
sAD are still not well understood and combine multiple
genetic and environmental risk factors. It is possible that
underlying mutations that have not yet been discovered
may play an important role in sAD, reflecting the inherent
variability of iPSCs. Thus, more cell lines have to be ana-
lyzed to reveal the broad heterogeneity of AD phenotypes.
We have demonstrated that another pathological hall-
mark characteristic of AD, TAU hyperphosphorylation,
could be detected in AD neurons. Conformational
changes and misfolded protein structure result in aber-
rant aggregation of TAU into neurofibrillary structures,
NFTs [73]. TAU phosphorylation at various sites affects
TAU activity, as well as its biological function and
pathogenic role. Studies on the physiological properties
of TAU have revealed that phosphorylation of Ser262
significantly diminishes the ability of TAU to bind mi-
crotubules [74]. Others have reported that phosphoryl-
ation of few KXGS motifs, including Ser262 and Ser356,
reduces TAU binding capacity to microtubules and thus
increases the dynamics of microtubules, which plays an
important role in neurite growth and the development
of neuronal polarity [75]. Phosphorylation at Thr231
leads to decreased ability of TAU to bind microtubules,
reduces the level of acetylated tubulin, and consequently
leads to microtubule destabilization [33]. Moreover, the
increased TAU phosphorylation at Ser396 and Ser404
impairs microtubule assembly by detachment of TAU
molecules from microtubules [76]. Elevated phosphoryl-
ation on Ser262, Thr231, and Ser396 residues can be
detected early in the AD disease process [77, 78].
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Quantitative in vitro data have revealed a negative
impact of TAU phosphorylation at many epitopes on
TAU activity and microtubule stability [31, 32, 79]. Pre-
vious studies on iPSC-derived, patient-specific fAD and
sAD neurons have been limited to detecting mostly
only one TAU phosphorylation site at Thr231 [40, 67].
We analyzed TAU phosphorylation in iPSC-derived
neurons from patients with fAD and patients with sAD
at six different phosphorylation sites. As a novel find-
ing, we demonstrated increased TAU phosphorylation
at all examined epitopes (Fig. 5a): Ser262, Ser202/
Thr205, Ser396, Ser400/Thr403/Ser404, Thr181, and
Thr231 in both fAD and sAD neurons. According to
the literature, phosphorylation of TAU at Ser262 and
Thr231 greatly diminishes its ability to bind micro-
tubules, by 35% and 25%, respectively [74], whereas
Ser396 and Ser404 phosphorylation generates more
fibrillogenic TAU in vitro [78], which shows an in-
creased propensity to aggregate [80]. Moreover, phos-
phorylation of the AT8 epitope results in a decrease in
TAU microtubule nucleation activity, leading to micro-
tubule depolymerization and destabilization [81]. TAU
phosphorylation increased during neural differentiation,
which is in agreement with in vivo studies on mice with
APP mutations [82].
Furthermore, we have shown higher levels of active
GSK3B in our AD cultures. This observation correlates
with previously described findings for which researchers
showed increased levels of active GSK3B measured in
fAD and sAD neurons in vitro [40] and in transgenic
animal models [83]. Pathological activation of GSK3B
establishes a feedforward loop that contributes to
abnormal APP processing [84], enhanced apoptosis in
hippocampal neurons, TAU hyperphosphorylation, and
synaptic failure in rodent models of AD [85, 86]. Our
findings revealed that activation of GSK3B might
contribute to TAU misregulation and abnormal phos-
phorylation. This is in accordance with previous reports
confirming the important role of GSK3B in regulating
TAU phosphorylation mostly on Thr231 and Ser199,
Ser396, Ser400, Ser404, and Ser413 [87]. Consistent with
this, restoring the normal level of GSK3B has been
shown to reduce TAU hyperphosphorylation, decrease
Aβ production and neuronal death in AD murine
models [88], and decrease Aβ-induced neurotoxicity in
cultured mouse primary neurons in vitro [89].
In our study, we evaluated cell viability after hydro-
gen peroxide and extracellular Aβ1–42 exposure in
neurons at different maturation stages. Exposure to
stress agents such as H2O2 induces ROS production
and toxicity in many different cell types [90–92]. ROS
show high reactivity with macromolecules and play an
important role as signaling molecules (reviewed in
[93]). Oxidative damage is linked with mitochondrial
abnormalities and is catalyzed by the presence of Fe
and Cu ions. In our results, we demonstrated a sig-
nificant H2O2 dose-related decrease in the survival of
fAD and sAD neurons. More mature neurons (TD56)
showed a greater sensitivity to H2O2 than younger
neuronal cultures (TD28). These observations indicate
that H2O2 may provoke an antioxidant stress re-
sponse resulting in increased level of ROS and may
lead to subsequent cell death. Additionally, we ob-
served that treatment with Aβ1–42 oligomers induced
cell death in both fAD and sAD neurons. According
to the literature, Aβ treatment may lead to activation
of glutamate receptors and inhibition of glutamate
transporters that leads to abnormal release of glutam-
ate and disturbances in glutamatergic neurotransmis-
sion. Aβ treatment induces NMDA receptor-mediated
cellular events in neurons and astrocytes, leading to
synaptic damage and spine loss [94]. Chronic stimula-
tion of NMDA receptor results in Ca2+ influx, which
activates apoptotic pathways and increased glutamate
excitotoxicity, leading to generation of ROS and to
neuronal damage and cell death [95]. In cortical
neurons, accumulation of glutamate and NMDA re-
ceptors promotes H2O2-mediated neurotoxicity and
oxidative damage in DNA.
Furthermore, increased influx of Ca2+ mediated by
Aβ treatment activates mitochondrial permeability
transition pore, leading to deregulation of respiratory
chain enzymes and ROS overproduction, and conse-
quently to neurotoxicity [96]. On the basis of the
above data, we can speculate that the neuronal death
observed in our cultures upon synthetic Aβ treatment
may be a consequence of mitochondrial stress and
higher ROS production.
It has previously been reported that accumulated Aβ
oligomers induce endoplasmic reticulum (ER) stress and
ROS production [97], which lead to membrane lipid per-
oxidation and impairment of membrane protein function
(reviewed in [98]). Furthermore, gene analysis of APP
E693Δ neurons revealed upregulation of the oxidative
stress-related markers [37]. Additionally, in vivo studies
showed increased protein oxidation and lipid peroxida-
tion in PSEN1 mutant brains [99, 100], leading to de-
struction of spine morphology and impaired synaptic
plasticity [101]. Thus, we speculate that our fAD and
sAD neurons may also exhibit increased levels of stress-
related gene expression, suggesting ER and Golgi abnor-
malities. It is worth considering that mutations in
PSEN1 and pathological changes in sAD, combined with
neuronal aging, can upregulate ROS production, leading
to mitochondrial damage that may contribute to neuro-
degenerative processes and AD progression.
Our results provide insight into the molecular basis of
AD and provide patient cell models that are relevant for
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further AD investigations. In all fAD and sAD lines, we
observed higher Aβ1–40 and Aβ1–42 secretion, increased
activation of GSK3B, and hyperphosphorylation of TAU
at six different epitopes. We showed that both fAD and
sAD neurons revealed AD phenotypes, suggesting that
sAD, with an unknown disease etiology, resembles the
fAD phenotype.
The results of this study provide strong evidence that
iPSC technology can be used in modeling the most com-
mon age-related neurodegenerative disorders, such as
AD. This new strategy will make it possible to study
pathological mechanisms on the molecular level and
analyze patient-derived neurons in vitro from individuals
who are still alive. Potentially, iPSCs from complex, un-
known genetic background diseases, such as sAD, may
be equally useful and able to provide suitable models
such as the monogenic forms of AD carrying mutations
in PSEN1, PSEN2, and APP.
Although iPSC-derived models afford the opportunity
to identify factors associated with disease phenotypes,
there are still many uncertainties that should be re-
solved in the near future. The most crucial limitations
that must be addressed in future studies include devel-
opment of reliable protocols for more rapid neuronal
differentiation and optimization of culture conditions
as well as current differentiation methods to eliminate
clonal variability and heterogeneity of differentiated
neuronal cells.
Several preclinical studies using fAD and sAD models
have established new methods to gather insight into the
molecular mechanisms, the role of different cell types,
and patient-specific drug response. We believe that
iPSCs have great potential for improving the model sys-
tems used in preclinical and clinical applications in neu-
rodegenerative diseases.
Conclusions
Our findings demonstrate that increased TAU phos-
phorylation occurs in fAD and sAD iPSC-derived ma-
ture neurons. To our knowledge, this is the first study
involving comparison of TAU protein hyperphosphory-
lation in an iPSC-based fAD and sAD model. We also
present evidence of elevated Aβ1–40 and Aβ1–42 levels
in fAD and sAD samples; however, the Aβ1–42/Aβ1–40
ratios are significantly different from control cell lines
in fAD cases, whereas the ratio of sAD cell lines not
differ significantly. Moreover, we have shown the more
sensitive oxidative stress response and higher suscepti-
bility to exogenously added synthetic Aβ1–42 peptide
solution of AD lines. Our findings demonstrate that the
iPSC technology is suitable to model both fAD and
sAD and may provide a platform for developing new
treatment strategies for these conditions.
Additional files
Additional file 1: Table S1. Antibodies used in this study. (TIF 141 kb)
Additional file 2: Figure S1. Characterization of Aβ secretion in control
and AD iPSC-derived neurons at TD14 and TD28. a The amount of
secreted Aβ1–40 and (b) Aβ1–42 from control-, fAD- (fAD-1–fAD-4), and
sAD- (sAD-1–sAD-6)-iPSC-derived neurons. c The ratio of Aβ1–42/Aβ1–40
from neurons derived from control and AD lines. Aβ1–40 and Aβ1–42
secreted from neural cells into the medium were measured at day 4
after the last medium change. The extracellular Aβ levels determined
(in picomolar concentrations) were normalized to total protein content.
Data represent mean ± SEM (n = 3). Because the detected levels of Aβ1–40
and Aβ1–42 were not significantly different between the four healthy
individual-derived clones (ctrl-1, ctrl-2, ctrl-3, ctrl-4), the average value
(±SEM) as a control value was used in all graphs. Dunnett’s test was
performed to evaluate the significance of groups compared with control
(*p < 0.05). (TIF 396 kb)
Additional file 3: Table S2. PCR primers used in this study.
(TIF 109 kb)
Additional file 4: Table S3. Polymorphism of AD- and FTD-related
genes and APOE status of cell lines used in this study. Footnote: Cell lines
not detailed in the table were not permitted to be involved in whole ex-
ome sequencing; therefore, only clinical mutation identification was avail-
able. (TIF 130 kb)
Additional file 5: Figure S2. Characterization of APP and APP-CTF
expression during neuronal differentiation. Densitometric analysis of
(a) APP and (b) APP-CTF expression in control neurons (ctrl-1), fAD-derived
neurons (fAD-1–fAD-4), and sAD-derived neurons (sAD-1–sAD-6) at TD42,
TD56, and TD70. Quantification of APP and APP-CTF signals was normalized
to GAPDH. Data are presented as mean ± SEM (n = 3). Dunnett’s test was
performed to evaluate the significance of groups compared with control
(*p < 0.05). (TIF 1295 kb)
Additional file 6: Figure S3. Western blot analysis of total TAU and
pTAU protein. a–e Densitometric analysis of TAU phosphorylated at
different epitopes: S262, S396, S202/T205, T181, and S400/T403/S404. All
samples were analyzed at days 42, 56, and 70 of terminal differentiation.
The amount of pTAU relative to total TAU levels in the lysates was
measured. GAPDH as the loading control was used to normalize the data.
All values are the mean ± SEM (n = 3). Dunnett’s test was performed to
evaluate the significance of groups compared with control (*p < 0.05).
(TIF 804 kb)
Additional file 7: Figure S4. Analysis of GSK3B and active form of
GSK3B in neuronal culture. a Quantification of active GSK3B form in
control neurons (ctrl-1), fAD neurons (fAD-1–fAD-4), and sAD neurons
(sAD-1–sAD-6) at days 42, 56, and 70 of terminal differentiation was
presented as a percentage of nonphosphorylated GSK3B at Ser9 (inactive
form of the kinase [102]). b Densitometric analysis of TAU phosphorylated at
T231 epitope at days 42, 56, and 70 of terminal differentiation. All values
were normalized to GAPDH and are presented as mean ± SEM (n = 3).
Dunnett’s test was performed to evaluate the significance of groups
compared with control (*p < 0.05). (TIF 384 kb)
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